Simulations Plus today announced the release of PKPlus version 2.5, an upgrade to our PK modeling platform with important new user-requested features.

Enhancements include improved data handling and command line functionality

Contacts

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced the launch of version 2.5 of PKPlus, an update to its software for analysis of preclinical and clinical trial data.

Mark Pflieger, product manager for PKPlus, said: “We delivered several important enhancements, including the simplification of pharmacokinetic (PK) data analyses, as well as automating and streamlining key routines. Special thanks to the dedicated team at Simulations Plus and those clients that provided important feedback for all their efforts.”

New features and enhancements of PKPlus 2.5 include:

  • Import CDISC SEND packages with PC domain as source data
  • Improved command line functionality
  • 64-bit system optimization for improved performance
  • Streamlined auto-reports
  • Additional workflow refinements

John DiBella, president of the Lancaster division for Simulations Plus, added: “As the client base for PKPlus has grown, we have engaged with users to identify the core functionality that they need to support the vast majority of their research activities. Throughout this effort, we’ve been, and continue to be, laser-focused on making our clients’ jobs easier with the enhancements in this new release. The demand for an affordable, commercially supported PK modeling platform remains strong, and we look forward to getting this version into the hands of industry scientists and students alike.”

View on demand the exciting new features in PKPlus 2.5 in the webinars section of the Simulations Plus website. In our commitment to support future generations of PK modelers, we continue to offer this version at no cost for academic institutions.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery/development software and a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney injury, and nonalcoholic fatty liver disease. Our software is used to conduct drug research by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading provider for physiologically based pharmacokinetic modeling and simulation. Visit us online www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

Follow us on Twitter | LinkedIn